Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 251 - 300 out of 5,901

Document Document Title
WO/2012/068981
Disclosed are 6-deoxy-6-thioether-amino acid cyclodextrin derivatives, obtained from condensation of amino acid derivatives with halo-cyclodextrin in the presence of a base. The 6-deoxy-6-thioether-amino acid cyclodextrin derivatives inc...  
WO/2012/067262
The present invention provides a therapeutic agent for diseases associated with skeletal muscle degeneration, which comprises a granular colony stimulation factor (G-CSF) as an active ingredient. This therapeutic agent is particularly ef...  
WO/2012/064090
The present invention provides a chemical preparation method of skeletal muscle-derived multipotent cells comprising: (a) a step for obtaining differentiated cells from mammals; and (b) a step for obtaining multipotent cells by treating ...  
WO/2012/064090
The present invention provides a chemical preparation method of skeletal muscle-derived multipotent cells comprising: (a) a step for obtaining differentiated cells from mammals; and (b) a step for obtaining multipotent cells by treating ...  
WO/2012/064090
The present invention provides a chemical preparation method of skeletal muscle-derived multipotent cells comprising: (a) a step for obtaining differentiated cells from mammals; and (b) a step for obtaining multipotent cells by treating ...  
WO/2012/058220
The present invention features anti-SODl antibodies and methods of using the antibodies for the treatment of amyotrophic lateral sclerosis (ALS) or the amelioration of symptoms associated with ALS.  
WO/2012/058220
The present invention features anti-SODl antibodies and methods of using the antibodies for the treatment of amyotrophic lateral sclerosis (ALS) or the amelioration of symptoms associated with ALS.  
WO/2012/054530
Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administering a composition comprising a chemosensory rece...  
WO/2012/053994
The present disclosure relates to ecdysteroid analogues which have similar, identical, or enhanced biological activities as compared to brassinosteroids, for instance similar, identical, or enhanced plant growth promoting activity. The e...  
WO/2012/053012
The present invention relates to stable pharmaceutical compositions of thiocolchicoside comprising nano size droplets of thiocolchicoside or salts thereof along with other pharmaceutically acceptable excipients. The present invention als...  
WO/2012/054527
Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administering a composition comprising a chemosensory rece...  
WO/2012/054535
The invention relates to classes of pharmaceutically-active heterocyclic compounds and pharmaceutically acceptable salts, and hydrates thereof, and compositions comprising the same. The invention also relates to methods for treating or p...  
WO/2012/054528
Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administering a composition comprising a chemosensory rece...  
WO/2012/053994
The present disclosure relates to ecdysteroid analogues which have similar, identical, or enhanced biological activities as compared to brassinosteroids, for instance similar, identical, or enhanced plant growth promoting activity. The e...  
WO/2012/053012
The present invention relates to stable pharmaceutical compositions of thiocolchicoside comprising nano size droplets of thiocolchicoside or salts thereof along with other pharmaceutically acceptable excipients. The present invention als...  
WO/2012/044783
The present invention provides embodiments which involve methods of providing a predetermined concentration of thymosin beta 4 (TB4) at a predetermined time, t, in a body portion of a live human patient. The methods can include determini...  
WO/2012/043393
[Problem] To provide an emulsion composition, an external skin preparation, and an analgesic, each of which is in a semi-solid state, has excellent thermal stability, and gives a good use sensation when applied to the skin. [Solution] An...  
WO/2012/043808
The purpose of the present invention is to provide: a heat shock protein expression inducer capable of inducing the in-vivo expression of HSP; food, drink, a pharmaceutical product, and a cosmetic containing the HSP expression inducer; a...  
WO/2012/039472
The purpose of the present invention is to provide a novel method which has an effect of ameliorating central nervous system inflammation. Provided is a drug against central nervous system inflammation which comprises a plasmalogen. Part...  
WO/2012/037083
A method of treating a musculoskeletal injury in a subject includes administering directly to a site of the musculoskeletal injury or to an area proximate the musculoskeletal injury an amount of SDF-1, MCP-3, or combinations thereof effe...  
WO/2012/036168
A composition that is for treating muscular dystrophy and that contains a SIRT1 activating factor as the active ingredient is provided. The composition may further contain a factor that imports SIRT1 to the nucleus. The present invention...  
WO/2012/034201
The present invention relates to a creatine-containing food supplement and method for preparing same. More specifically, the present invention relates to a creatine-containing food supplement formulation compressed into chewable and pala...  
WO/2012/036152
The present invention provides a high purity heparin useful as a medicine, a cosmetic, a research reagent and the like, and a production method therefor, in more detail, a method for producing heparin, the method comprising mixing a hepa...  
WO/2012/037083
A method of treating a musculoskeletal injury in a subject includes administering directly to a site of the musculoskeletal injury or to an area proximate the musculoskeletal injury an amount of SDF-1, MCP-3, or combinations thereof effe...  
WO/2012/033070
[Problem] To provide a pharmaceutical product, especially a pharmaceutical composition which is useful for the treatment of pain. [Solution] The inventors have intensively studied using pain model animals for the purpose of providing a t...  
WO/2012/029994
The present invention provides a prophylactic or therapeutic agent for amyotrophic lateral sclerosis, containing a 1,3-diphenylurea derivative or multikinase inhibitor.  
WO/2012/030919
The invention provides methods for muscle repair or regeneration comprising administering therapeutically effective amounts of RAR agonists or stem cells that are pretreated with contact with a RAR agonist to a subject at a site of muscl...  
WO/2012/030919
The invention provides methods for muscle repair or regeneration comprising administering therapeutically effective amounts of RAR agonists or stem cells that are pretreated with contact with a RAR agonist to a subject at a site of muscl...  
WO/2012/029986
Disclosed is a drug which efficiently allows skipping of the 53rd exon in the human dystrophin gene. Disclosed is an oligomer which makes possible skipping of the 53rd exon of the human dystrophin gene.  
WO/2012/027570
Engineered multivalent and multispecific binding proteins, methods of making, and their uses in the prevention, diagnosis, and/or treatment of disease are provided.  
WO/2012/026575
[Problem] The purpose of the present invention is to provide a muscle-enhancing agent. The purpose of the present invention is also to provide food having a muscle-enhancing effect. [Solution] The inventors focused on the effects that Wa...  
WO/2012/024242
There are disclosed selective myostatin antagonists (including antibodies), nucleic acids encoding them, and methods of making and using them. Neutralizing antibodies recognizing the conformational epitope near position 21 to 31 and posi...  
WO/2012/019002
A population of somatic stem cells and a method of preparing same. Also disclosed are two subpopulations thereof and their various uses.  
WO/2012/019071
The present invention provides methods and compositions useful for the treatment and/or prevention of sarcopenia. The compositions include one or more of the following benzothiazepine, benzoxazepine, benzodiazepine or benzazepine compoun...  
WO/2012/019002
A population of somatic stem cells and a method of preparing same. Also disclosed are two subpopulations thereof and their various uses.  
WO/2012/016930
The present invention relates to the compound of formula (I) for use in the treatment of a nonsense-mutation-mediated genetic disease.  
WO/2012/018257
The invention relates to means and methods for removing a proteolytic cleavage site from a protein comprising providing a cell that expresses pre-m RNA encoding said protein with an anti-sense oligonucleotide that induces skipping of the...  
WO/2012/012843
The present invention provides novel compounds of the Formula (1), pharmaceutical compositions comprising such compounds and methods for using such compounds as tools for biological studies or as agents or drugs for modulating Protease A...  
WO/2012/014890
Provided are: a nucleic acid molecule capable of binding to c-Met, which is a substance that can be used for analysis of the mechanism of development, diagnosis and treatment of diseases that are induced by c-Met; and use of the nucleic ...  
WO/2012/014994
Provided is a compound which can regulate a VCP activity. Specifically provided is a compound represented by formula (I) (wherein R is as defined in the description) or an oxide, ester, prodrug, pharmaceutically acceptable salt or solvat...  
WO/2012/012300
Provided herein are methods for ameliorating an adverse effect of systemic administration of a PEG hyaluronan degrading enzyme to a subject. The methods involve systemically administering a PEGylated hyaluronan degrading enzyme, particul...  
WO/2012/011673
The present invention relates to a promoter of muscle cell differentiation or renewal, to a pharmaceutical composition for treating or preventing muscular impairment, and to a food composition for alleviating or preventing muscular impai...  
WO/2012/011673
The present invention relates to a promoter of muscle cell differentiation or renewal, to a pharmaceutical composition for treating or preventing muscular impairment, and to a food composition for alleviating or preventing muscular impai...  
WO/2012/011548
The present invention provides a nitrogen-containing heterocyclic derivative which has ASK1-inhibitory activity and is useful as a prophylactic and/or therapeutic agent for ALS and so on, or a pharmaceutically acceptable salt thereof. Th...  
WO/2012/012300
Provided herein are methods for ameliorating an adverse effect of systemic administration of a PEG hyaluronan degrading enzyme to a subject. The methods involve systemically administering a PEGylated hyaluronan degrading enzyme, particul...  
WO/2012/011572
It has been discovered that carnitine, a derivative thereof or a pharmaceutically acceptable salt thereof is useful as an active ingredient of a prophylactic or therapeutic agent for diastolic heart failure. The present invention is capa...  
WO/2012/011591
Disclosed is a compound that has excellent pharmacological activity, physicochemical qualities, and the like, and is useful in the prevention/treatment of eicosanoid-related conditions including arteriosclerosis, diabetes, obesity, ather...  
WO/2012/008457
The present invention provides a composition for external application, which contains a vitamin A, a heparin analogue and an antioxidant. The present invention also provides a composition for external application for improving rough skin...  
WO/2012/006864
Disclosed are a series of pentacyclic triterpenoid compounds, preparation methods and uses thereof. The compounds have anti-inflammatory, anti-tumor, anti-bacterial and antiviral activities, and they can be used for treating urinary inco...  
WO/2012/009474
The present invention relates to compositions and methods for treating sialic acid deficiencies comprising extended release formulations.  

Matches 251 - 300 out of 5,901